Lopinavir
Other / unclassified targets CYP17A1, CYP21A2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Kaletra | — | 2001-03-19 | europa.eu ↗ |
| Approved | US (FDA) | KALETRA | — | 2000-09-15 | fda.gov ↗ |
Trials 136 · started per year
Also used as a comparator or background therapy in 110 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03070470 Comparator | Mar → Jun 2017 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02631473 Comparator | Nov 2015 → Nov 2017 | HIV infectious disease | St Stephens Aids Trust | Suspended | No outcome recorded |
| Phase 1 | NCT02203461 Comparator | Jul → Oct 2014 | — | Technical University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT00833378 Comparator | Jan → Mar 2009 | hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00531999 Comparator | Oct 2007 → Aug 2008 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT00266058 Comparator | Dec 2005 → Nov 2010 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04390152 Comparator | Jan 2020 → Mar 2022 | acute respiratory distress syndrome | BioXcellerator | Terminated | No outcome recorded |
| Phase 1/2 | NCT00004578 Comparator | Nov 1997 → Apr 2005 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT04521400 Background | Aug → Sep 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04374539 Comparator | Apr 2020 → Jun 2021 | COVID-19 | Fundacion Clinic per a la Recerca Biomédica | Terminated | No outcome recorded |
| Phase 2 | NCT04343768 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04276688 Comparator | Feb → Mar 2020 | COVID-19 | The University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT02415985 Background | Jun 2015 → Dec 2019 | HIV infectious disease, tuberculosis | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 2 | NCT02116660 Comparator | Sep 2014 → Jul 2017 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01125696 Background | May 2012 → May 2018 | HIV infectious disease, hepatitis B virus infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00945282 Background | Oct → Nov 2009 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00827112 Background | Mar 2009 → Jul 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00665847 Background | Nov 2008 → May 2011 | — | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00654147 Comparator | Apr 2008 → Jan 2012 | HIV infectious disease | Margaret A. Fischl, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT01174914 Comparator | Mar 2008 → Mar 2010 | — | The Ojai Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00084149 Background | Feb 2004 → Jan 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00043953 Background | Aug 2002 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00006144 Background | Oct 2000 → Apr 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT04475120 Comparator | Apr → Jul 2020 | COVID-19 | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 2/3 | NCT04331470 Background | Apr 2020 | COVID-19 | Fasa University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT02285114 Background | Jan 2015 → Nov 2019 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02016924 Background | Jan 2014 → Jun 2025 overdue | AIDS | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01923311 Background | Aug 2013 → Nov 2017 | AIDS | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT01154673 Background | Nov 2011 → Sep 2014 | — | University of Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT00834457 Comparator | Jun 2007 → Jul 2009 | Kaposi's sarcoma | Parirenyatwa Hospital | Completed | No outcome recorded |
| Phase 346 trials | ||||||
| Phase 3 | NCT04403100 Comparator | Jun 2020 → Feb 2021 | COVID-19, respiratory tract infectious disorder | Cardresearch | Unknown | No outcome recorded |
| Phase 3 | NCT04364022 Comparator | Apr 2020 → Mar 2021 | — | Calmy Alexandra | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03256422 Background | Sep 2017 → Aug 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02671383 Comparator | Jun 2016 → May 2018 | HIV infectious disease | Willem Daniel Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT02616783 Comparator | Dec 2015 → Feb 2018 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02605954 Comparator | Nov 2015 → Jun 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02469246 Background | Jun 2015 → Dec 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02397096 Background | Jun 2015 → Feb 2018 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02269917 Comparator | Mar 2015 → Feb 2017 | HIV infectious disease | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 3 | NCT02227238 Comparator | Dec 2014 → Aug 2017 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02302547 Comparator | Dec 2014 → Aug 2017 | HIV infectious disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT02157311 Background | Jul 2014 → Jan 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02219672 Comparator | Jul 2014 → Jul 2016 | AIDS | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 3 | NCT02121795 Background | May 2014 → Aug 2015 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02155101 Comparator | May 2014 → Jun 2016 | HIV infectious disease | University of Liverpool | Completed | No outcome recorded |
| Phase 3 | NCT01905059 Comparator | Feb 2014 → Apr 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01480713 Background | May 2012 → May 2014 | HIV infectious disease | IrsiCaixa | Completed | No outcome recorded |
| Phase 3 | NCT01255371 Comparator | Mar 2012 → May 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Withdrawn | No outcome recorded |
| Phase 3 | NCT01516970 Comparator | Nov 2011 → Aug 2013 | HIV infectious disease | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01475838 Comparator | Nov 2011 → Nov 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01237444 Comparator | Dec 2010 → May 2012 | HIV infectious disease | Pedro Cahn | Completed | No outcome recorded |
| Phase 3 | NCT01252940 Background | Nov 2010 → Jan 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00988039 Comparator | Mar 2010 → Jan 2014 | HIV infectious disease | Medical Research Council | Completed | No outcome recorded |
| Phase 3 | NCT00936195 Comparator | Jan 2010 → Jan 2013 | HIV infectious disease, pregnancy disorder | French National Agency for Research on AIDS and Viral Hepatitis | Withdrawn | No outcome recorded |
| Phase 3 | NCT00928187 Comparator | Nov 2009 → Sep 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00443729 Comparator | May 2007 → Oct 2008 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00443703 Comparator | May 2007 → Apr 2009 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00454337 Background | May 2007 → Sep 2008 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00358917 Comparator | Aug 2006 → Nov 2008 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00302822 Background | Apr 2006 → Dec 2009 | AIDS | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00234091 Comparator | Apr 2006 → Sep 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00272779 Comparator | Nov 2005 → Jun 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00262522 Comparator | Nov 2005 → Jul 2008 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00258557 Comparator | Sep 2005 → Jun 2007 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 3 | NCT00105079 Comparator | Apr 2005 → Aug 2007 | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00234910 Background | Jan 2005 → Jun 2007 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00135395 Comparator | May 2004 → Feb 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00164736 Comparator | Mar 2004 → Jan 2010 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT00120393 Comparator | Jan 2004 → May 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00234923 Comparator | Aug 2003 → Feb 2007 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01003990 Comparator | Oct 2002 → Feb 2016 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00035932 Comparator | Nov 2001 → Jul 2003 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00966160 Comparator | Jan 1999 → Dec 2008 | AIDS | University of Cologne | Completed | No outcome recorded |
| Phase 424 trials | ||||||
| Phase 4 | NCT04779047 Comparator | Oct 2020 → Mar 2021 | COVID-19, pneumonia | October 6 University | Unknown | No outcome recorded |
| Phase 4 | NCT04350671 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04350684 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04286503 Comparator | Feb 2020 → Feb 2021 | COVID-19 | Beijing YouAn Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02198443 Comparator | Jun 2015 → Jul 2016 | HIV infectious disease | Fundacion Clinic per a la Recerca Biomédica | Completed | No outcome recorded |
| Phase 4 | NCT01576731 Comparator | Jul 2012 → Jul 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01637259 Comparator | Jun 2012 → Dec 2015 | HIV infectious disease, proteinuria | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01533272 Comparator | Feb 2012 → Jun 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01192035 Comparator | May 2011 → Sep 2014 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01116817 Comparator | Aug 2010 → Jun 2011 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01513122 Comparator | Feb 2010 → Sep 2012 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00994344 Comparator | Oct 2009 → Oct 2012 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00931463 Background | Sep 2009 → Sep 2012 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00772902 Background | Oct 2008 → Sep 2009 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00775606 Comparator | Oct 2008 → Dec 2010 | AIDS | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00759070 Comparator | Sep 2008 → Jul 2013 | HIV infectious disease | Juan A. Arnaiz | Unknown | No outcome recorded |
| Phase 4 | NCT00444379 Comparator | Apr 2007 → Feb 2012 | HIV infectious disease, Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00438152 Comparator | Sep 2006 → Feb 2009 | HIV infectious disease | Royal Free Hampstead NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT00281606 Comparator | Feb 2006 → Oct 2007 | HIV infectious disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00244712 Comparator | Jul 2005 → Apr 2008 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01445223 Comparator | Apr 2004 → Dec 2009 | HIV infectious disease | Göteborg University | Completed | No outcome recorded |
| Phase 4 | NCT00648999 Comparator | Nov 2003 → Dec 2006 | HIV infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT00335686 Comparator | Oct 2003 → Mar 2006 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00234975 Comparator | Oct 2002 → Jan 2008 | HIV infectious disease | AbbVie | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT05044962 Comparator | Nov 2021 → Mar 2027 expected | HIV infectious disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT04380818 Background | Jun 2020 → Sep 2021 | viral pneumonia | Grupo de Investigación Clínica en Oncología Radioterapia | Unknown | No outcome recorded |
| — | NCT04394182 Background | Apr → Dec 2020 | cytokine release syndrome, viral pneumonia | Fundacion GenesisCare | Suspended | No outcome recorded |
| — | NCT04376814 Comparator | Mar → Apr 2020 | COVID-19 | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
| — | NCT04295551 Background | Mar → Jul 2020 | COVID-19 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| — | NCT04261907 Comparator | Feb → Apr 2020 | COVID-19 | First Affiliated Hospital of Zhejiang University | Terminated | No outcome recorded |
| — | NCT04251871 Comparator | Jan 2020 → Jan 2021 | COVID-19 | Beijing 302 Hospital | Unknown | No outcome recorded |
| — | NCT01583439 Background | Sep 2012 → Feb 2013 | HIV infectious disease | Harvard School of Public Health (HSPH) | Terminated | No outcome recorded |
| — | NCT01614405 Comparator | Jun 2012 → Jul 2015 | primary biliary cholangitis | University of Alberta | Terminated | No outcome recorded |
| — | NCT00413153 Comparator | May 2006 → Dec 2008 | HIV infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 254 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lopinavir | “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗239“Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL...” NCT00120393 ↗ “This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed...” NCT00085943 ↗ “Six hundred and eighty-eight antiretroviral-naive, HIV-1-infected patients were randomized in this double-blind, placebo-matched, multicenter, noninferiority study to receive a...” PMID 19542866 ↗ Jul 2009 “ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as...” NCT05044962 ↗ “one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir...” NCT01614405 ↗ “The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and...” NCT00753324 ↗ “Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised...” PMID 17617272 ↗ Jul 2007 “Evaluation of the Pharmacokinetics and Tolerability of Increased Dosage of Lopinavir/Ritonavir(LPV/r) in Individuals Experiencing Viremia on Standard Dose LPV/r Using LPV/r...” NCT00414284 ↗ “Tenofovir / emtricitabine + lopinavir / ritonavir for all HIV-1+2-infected patients and all women who do not use effective contraception or who have a history of nevirapine use...” NCT00495651 ↗ “Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the...” NCT02397096 ↗ “Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.” NCT02269917 ↗ “Tenofovir+Emtricitabine+Third agent (Including a ritonavir-boosted protease inhibitor : saquinavir or indinavir or fosamprenavir or tipranavir or darunavir or atazanavir or lopinavir” NCT02302547 ↗ “(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine” NCT02513147 ↗ “Atazanavir (300 mg once daily) and lopinavir (400 mg twice daily), each with low-dose ritonavir, achieved similar IQs in HIV-infected, treatment-naive patients.” PMID 22121190 ↗ Nov 2011 “emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day” NCT00454337 ↗ “Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir.” NCT01252940 ↗ “atazanavir 300 mg and ritonavir 100 mg once daily or lopinavir 400 mg and ritonavir 100 mg twice daily plus two NRTIs; boosted protease inhibitor group” PMID 40883049 ↗ Sep 2025 “Kaletra® (lopinavir+ritonavir) is a combination of two protease inhibitors: lopinavir plus a low dose of ritonavir, enhancing the action of the former.” NCT00865475 ↗ “Population PK models were developed for lopinavir (LPV) and ritonavir (RTV) to evaluate the impact of RTV on the oral clearance (CL/F) of LPV.” PMID 38247190 ↗ Jan 2024 “Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg” NCT00708162 ↗ “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.” NCT02155101 ↗ “Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.” NCT01031849 ↗ “Tenofovir (TDF) and ritonavir-boosted lopinavir (LPV/r) were not introduced to China as second-line medications until 2009.” PMID 25821963 ↗ Mar 2015 “Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.” NCT07002242 ↗ “As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.” NCT00772902 ↗ “Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.” NCT03836833 ↗ “Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.” PMID 19487905 ↗ Aug 2009 “Lopinavir/ritonavir (LPV/r) is widely used protease inhibitor because of its high efficacy and high genetic barrier.” NCT00627055 ↗ “allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)” NCT01475838 ↗ “The aim of this study was to determine the impact of sex on the pharmacokinetics of lopinavir/ritonavir.” PMID 17615254 ↗ Jul 2007 “atazanavir (ATV) plus ritonavir (RTV) or lopinavir (LPV)/RTV are the preferred boosted PI options.” NCT02227238 ↗ “oral lopinavir 400 mg and oral ritonavir 100 mg twice daily plus oral lamivudine 300 mg once daily” PMID 26062880 ↗ Jun 2015 “TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension” NCT05850728 ↗ “Kaletra® is 2 protease inhibitors (lopinavir and ritonavir) combined in one dosage form.” NCT00508222 ↗ “Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)” NCT00437476 ↗ “allowed boosted 3rd ARV agents: lopinavir (LPV), atazanavir (ATV), darunavir (DRV)” NCT02285114 ↗ “Salvage Therapy With Amprenavir, Lopinavir and Ritonavir 200 mg/d or 400 mg/d” NCT00196625 ↗ “Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours” NCT01480713 ↗ “Lopinavir/ritonavir 400/100mg bid or Lopinavir/ritonavir 600/150mg bid” NCT01138202 ↗ “once daily Kaletra dosed at 800mg lopinavir with 200mg ritonavir” NCT00679926 ↗ “lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID” NCT00827112 ↗ “Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily” NCT00988039 ↗ “Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL)” NCT00752856 ↗ “Kaletra: lopinavir/ritonavir: 2c/12h 7 days” NCT04374539 ↗ “lopinavir/ritonavir cps 200/50 mg, 2x2/day” NCT04475120 ↗ “lopinavir boosted by ritonavir (LPV/r)” NCT02016924 ↗ “lopinavir+ritonavir (LPV/r; Kaletra®)” NCT02616783 ↗ “lopinavir/ritonavir (LPV/r; Kaletra®)” NCT02605954 ↗ “(lopinavir (LPV) and ritonavir (RTV))” NCT02256826 ↗ “ritonavir boosted lopinavir (LPV/r)” NCT02469246 ↗ “ritonavir-boosted lopinavir (LPV/r)” NCT02121795 ↗ “Lopinavir / Ritonavir （LPV/r)）” NCT02231281 ↗ “either lopinavir [LPV]” NCT00665847 ↗ “lopinavir (LPV)” NCT03631732 ↗ “lopinavir” NCT00766818 ↗ “lopinavir” NCT01637259 ↗ |
| Known as | A-157378-0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL729 ↗ |
| Known as | ABT-378 | ChEMBL registry synonym — accepted as the source's own label CHEMBL729 ↗ |
| Known as | Aluviran | ChEMBL registry synonym — accepted as the source's own label CHEMBL729 ↗ |
| Known as | Kaletra | “Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r.” NCT01923311 ↗2“400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories)” NCT00966160 ↗ “Kaletra (lopinavir [LPVr])” NCT00192621 ↗ |
| Known as | Koletra | ChEMBL registry synonym — accepted as the source's own label CHEMBL729 ↗ |
| Known as | Lopinavir component of kaletra | ChEMBL registry synonym — accepted as the source's own label CHEMBL729 ↗ |
| Known as | Lopinavir, (s-(2s,4s,5s))- | ChEMBL registry synonym — accepted as the source's own label CHEMBL729 ↗ |
| Known as | Lopinavir/r | “The study-treatment were lopinavir/r 100/400mg bid or indinavir/r 100/400mg bid for PI-class, for NNRTI-class, efavirenz or nevirapine and all NRTIs except D4T and DDC at usual dosage.” NCT00122668 ↗6“Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r.” NCT01923311 ↗ “protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r” NCT03256422 ↗ “Azidothimidine + lamivudine + lopinavir/r Or” NCT01174914 ↗ “lopinavir/r,” NCT02157311 ↗ |
| Known as | Lopinavirum | ChEMBL registry synonym — accepted as the source's own label CHEMBL729 ↗ |
| Known as | LPV | “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗18“The ANRS 12174 trial assessed the efficacy and tolerance of lopinavir (LPV)-ritonavir (LPV/r) prophylaxis versus those of lamivudine (3TC) prophylaxis administered to breastfed...” PMID 27895016 ↗ Jan 2017 “Lopinavir (LPV) plasma AUC(0,τ), C(max) and Cτ decreased by 23%, 14% and 40%, respectively, following administration of lopinavir/ritonavir with GSK2248761.” PMID 22288567 ↗ Aug 2012 “Population PK models were developed for lopinavir (LPV) and ritonavir (RTV) to evaluate the impact of RTV on the oral clearance (CL/F) of LPV.” PMID 38247190 ↗ Jan 2024 “The two combinations are abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) and zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LPV/RTV).” NCT00086359 ↗ “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)” NCT01475838 ↗ “boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)” NCT01905059 ↗ “allowed boosted 3rd ARV agents: lopinavir (LPV), atazanavir (ATV), darunavir (DRV)” NCT02285114 ↗ “Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy.” PMID 19237646 ↗ Feb 2009 “Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)” NCT00759070 ↗ “3) lopinavir (LPV)/RTV plus additional RTV.” NCT00027339 ↗ “(lopinavir (LPV) and ritonavir (RTV))” NCT02256826 ↗ “Lopinavir (LPV) 200 mg tablets” NCT02116660 ↗ “either lopinavir [LPV]” NCT00665847 ↗ “lopinavir (LPV)/RTV” NCT00025727 ↗ “lopinavir (LPV)” NCT03631732 ↗ |
| Known as | LPV/r | “ritonavir boosted lopinavir (LPV/r)” NCT02469246 ↗1“Kaletra (lopinavir [LPVr])” NCT00192621 ↗ |
| Known as | NANO-Lopinavir | “a new pharmaceutical formulation of lopinavir (NANO-lopinavir) in HIV negative healthy volunteers” NCT02631473 ↗ |
| Action | Inhibit | “BACKGROUND: With increasing recognition of the benefits of early antiretroviral therapy initiation in perinatally HIV-infected infants, data are needed regarding the...” PMID 19209098 ↗ Mar 2009 |
| Modality | Other / unclassified | “lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group)” PMID 20554983 ↗ Jun 2010 |
| Route | Oral | “when administered orally in antiretroviral-HIV-1 infected subjects” NCT00004578 ↗ |
| Target | CYP17A1 | “Lopinavir, but not ritonavir, inhibited CYP17A1 and CYP21A2 activity in H295R cells.” PMID 31633158 ↗ Aug 2020 |
| Target | CYP21A2 | “Lopinavir, but not ritonavir, inhibited CYP17A1 and CYP21A2 activity in H295R cells.” PMID 31633158 ↗ Aug 2020 |